Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors
Rita E. Chen(Washington University in St. Louis), Michael Diamond(Washington University in St. Louis), Jane A. O’Halloran(St. Vincent's University Hospital), Wooseob Kim(Korea University), Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), Salim Chahin(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Scott A. Handley(Washington University in St. Louis), Alfred H.J. Kim(Unknown), Laura A. VanBlargan(Washington University in St. Louis), Rachel M. Presti(Johns Hopkins University), Matthew J. Gorman(Ragon Institute of MGH, MIT and Harvard), Samantha Burdess(Washington University in St. Louis), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Lindsay Droit(Washington University in St. Louis), Douglas A. Lauffenburger(Harvard University), Gregory F. Wu(University of Pennsylvania), Jackson S. Turner(Washington University in St. Louis), Florian Krammer(Semmelweis University), Daniel Y. Zhu(Massachusetts Institute of Technology), Michael Paley, Dansu Yuan(Ragon Institute of MGH, MIT and Harvard), Parakkal Deepak(Washington University in St. Louis)
Cited by 36
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation
|Cell Metabolism|2016|1.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
The continued threat of emerging flaviviruses
|Nature Microbiology|2020|1.1k